{
    "root": "75484338-6d78-877c-086f-61467c8dd5e4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eslicarbazepine Acetate",
    "value": "20250130",
    "ingredients": [
        {
            "name": "ESLICARBAZEPINE ACETATE",
            "code": "BEA68ZVB2K",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_87016"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        }
    ],
    "indications": {
        "text": "eslicarbazepine acetate tablets indicated treatment partial-onset seizures patients 4 years age older .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 adult patients : recommended initial eslicarbazepine acetate 400 mg daily . patients , treatment may initiated 800 mg daily need seizure reduction outweighs increased risk . increase dose weekly increments 400 mg 600 mg daily , based response tolerability , recommended maintenance 800 mg 1,600 mg daily . ( 2.2 ) \u2022 pediatric patients : recommended eslicarbazepine acetate based body weight administered orally daily . increase dose weekly intervals based response tolerability , recommended maintenance ( 2.2 ) . \u2022 patients moderate severe renal impairment : reduce 50 % . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "eslicarbazepine acetate tablets contraindicated patients hypersensitivity eslicarbazepine acetate oxcarbazepine [ ( 5.2 , 5.3 , 5.4 ) ] .",
    "indications_original": "Eslicarbazepine acetate tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older.",
    "contraindications_original": "\u2022 Adult Patients: The recommended initial dosage of eslicarbazepine acetate is 400 mg once daily. For some patients, treatment may be initiated at 800 mg once daily if the need for seizure reduction outweighs an increased risk of adverse reactions. Increase the dose in weekly increments of 400 mg to 600 mg once daily, based on clinical response and tolerability, to a recommended maintenance dosage of 800 mg to 1,600 mg once daily. ( 2.2 ) \u2022 Pediatric Patients: The recommended dosage of eslicarbazepine acetate is based on body weight and is administered orally once daily. Increase the dose in weekly intervals based on clinical response and tolerability, to the recommended maintenance dosage ( 2.2 ). \u2022 Patients with Moderate or Severe Renal Impairment: Reduce dosage by 50%. ( 2.4 )",
    "adverseReactions_original": "Eslicarbazepine acetate tablets are contraindicated in patients with a hypersensitivity to eslicarbazepine acetate or oxcarbazepine [see Warnings and Precautions (\n                     5.2\n                     , \n                     5.3\n                     , and \n                     5.4\n                     )].",
    "drug": [
        {
            "name": "Eslicarbazepine Acetate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_87016"
        }
    ]
}